Biopharma Summit 2024

Join us at the virtual SelectScience^® Biopharma Summit, celebrating its fourth year, as we bring together the biopharmaceutical community and leading manufacturers to cultivate collaboration and exchange vital updates in biopharma.

Attend expert-led scientific presentations as we explore crucial topics such as bioprocess optimization, quality control in biomanufacturing, innovations in cell culture technology, cell and gene therapy, antibody characterization, biosimilars, and much more. Plus, acquire practical skills through engaging technology showcases, explore resource hubs featuring the latest advancements from industry leaders, and strengthen your professional network by forging impactful collaborations.

Why attend?

Keep up with cutting-edge developments from expert speakers
Access the latest written guides, posters, technical papers, and more in our resource hubs
Discover new technology launches and innovations
Ask the experts – live Q&As with guest speakers and manufacturers
Join the free virtual event from the comfort of your home, office, or lab

Agenda

11:00
	Opening address & Poster session
11:15 12:15 (CEST) 06:15 (EDT) 03:15 (PDT)

	Cost-effectiveness of chimeric antigen receptor (CAR) T-cell therapy for blood cancers: A systematic review Nishma Patel, Health Economist, University College London
12:00 13:00 (CEST) 07:00 (EDT) 04:00 (PDT)

	Biomarkers as linkers between preclinical, clinical, and patient outcome Dr. Matt Harwood, Principal Scientist Certara UK (Simcyp Division)
12:45 13:45 (CEST) 07:45 (EDT) 04:45 (PDT)

	Combining DNA encoded libraries with machine learning to accelerate drug discovery Joe Franklin, Senior Vice President of Early Discovery, Anagenex
13:30 14:30 (CEST) 08:30 (EDT) 05:30 (PDT)

	New bioprocess strategy with fiber chromatographic clarification platform from discovery to manufacturing Dr. Masa Nakamura, Bioprocess Science Senior Specialist, Solventum
14:15 15:15 (CEST) 09:15 (EDT) 06:15 (PDT)

	Talk title to be announced Dr. Andrew Mahan, Associate Director at The Janssen Pharmaceutical Companies of Johnson & Johnson
15:00 16:00 (CEST) 10:00 (EDT) 07:00 (PDT)
	Proteomic analysis identified treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver disease Dr. Jen-Chieh Chuang, Director, Translational Med & Biomarker, Early Clinical Development, GITAU, Takeda Pharmaceuticals
15:45 16:45 (CEST) 10:45 (EDT) 07:45 (PDT)

	5 benefits of base editing to go beyond conventional CRISPR Amanda Haupt, Business Unit Manager, Base Editing, Revvity
16:30 17:30 (CEST) 11:30 (EDT) 08:30 (PDT)

	GLP-1 peptide and intact mAb characterization using the Agilent ExD cell Dr. Joseph Meeuwsen, Product Manager ExD, Agilent Technologies, Inc
17:15 18:15 (CEST) 12:15 (EDT) 09:15 (PDT)

	Guiding decisions throughout drug development: Localize critical PTMs at the sub-unit level Dr. Scott Mack, Principal Scientist, SCIEX